Screening for proteinuria in ‘at-risk’ patients with spinal cord injuries: lessons learnt from failure by Subramanian Vaidyanathan et al.
Vaidyanathan et al. Patient Safety in Surgery 2014, 8:25
http://www.pssjournal.com/content/8/1/25SHORT REPORT Open AccessScreening for proteinuria in ‘at-risk’ patients with
spinal cord injuries: lessons learnt from failure
Subramanian Vaidyanathan1*, Kottarathil Abraham Abraham2, Gurpreet Singh3, Bakul Soni1 and Peter Hughes4Abstract
Spinal cord injury patients may develop proteinuria as a result of glomerulosclerosis due to urosepsis, hydronephrosis,
vesicoureteric reflux, and renal calculi. Proteinuria in turn contributes to progression of kidney disease. We report one
paraplegic and two tetraplegic patients, who developed recurrent urine infections, urinary calculi, and hydronephrosis.
These patients required several urological procedures (nephrostomy, cystoscopy and ureteric stenting, ureteroscopy
and lithotripsy, extracorporeal shock wave lithotripsy). These patients had not received antimuscarinic drugs nor had
they undergone video-urodynamics. Proteinuria was detected only at a late stage, as testing for proteinuria was not
performed during follow-up visits. Urine electrophoresis showed no monoclonal bands in any; Serum glomerular
basement membrane antibody screen was negative. Serum neutrophil cytoplasmic antibodies screen by fluorescence
was negative. All patients were prescribed Ramipril 2.5 mg daily and there was no further deterioration of renal function.
Spinal cord injury patients, who did not receive antimuscarinic drugs to reduce intravesical pressure, are at high risk for
developing reflux nephropathy. When such patients develop glomerulosclerosis due to recurrent urosepsis, renal calculi,
or hydronephrosis, risk of proteinuria is increased further. Take home message: (1) Screening for proteinuria should be
performed regularly in the ‘at-risk’ patients. (2) In the absence of other renal diseases causing proteinuria, spinal cord
injury patients with significant proteinuria may be prescribed angiotensin-converting enzyme inhibitor or angiotensin-II
receptor antagonist to slow progression of chronic renal disease and reduce the risk of cardiovascular mortality.
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A cross-sectional analyses of Veterans with spinal cord
injury and disorders across all VA facilities of USA in
2006.revealed that 1 in 3 Veterans with had chronic
kidney disease [1]. The United Kingdom national guide-
lines on ‘chronic spinal cord injury: management of
patients in acute hospital settings’, state that urinary
assessment should include review of voiding method
and pattern; 24-hour voided volume chart; post-void
residual volume (by catheter or bladder scan), if voiding
on urge or by reflex; urinary microscopy and culture, if
symptoms or signs of local or systemic infection [2].
There is no mention of testing for proteinuria. The
Consortium for Spinal Cord Medicine consisting of
seventeen organizations, including the Paralyzed Veterans
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article, unless otherwise stated.spinal cord medicine [3]. Bladder management for
adults with spinal cord injury recommends a urologic
evaluation every year, although there is no consensus
among doctors on the frequency this type of exam
should be performed or the range of tests that should
be included. The important components of the urologic
evaluation are an assessment of both the upper and lower
tracts. Upper tract evaluations include tests that evaluate
function, such as renal scans and tests that evaluate
anatomy, such as ultrasound, CT scans, and intravenous
pyelograms (IVP). Renal scans are frequently used to
screen the upper tract because they are not user
dependent, do not have a risk of allergic reactions, do
not require a bowel preparation, and cause much less
radiation exposure than a CT scan or IVP. Lower tract
evaluations include urodynamics to determine bladder
function, cystograms to evaluate for vesicoureteral
reflux, and cystoscopy to evaluate bladder anatomy.
Thus testing for proteinuria does not appear to be a
mandatory investigation. In North West Regional Spinalentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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creatinine, and eGFR), and ultrasound examination of
urinary tract are carried out during follow-up of spinal
cord injury patients. No test is done to detect protein-
uria during follow-up.
Wall and associates [4] found following independent
predictors for the development of proteinuria in spinal
cord injury patients by using logistic stepwise multiple
linear regression analysis: (1) Use of chronic indwelling
bladder catheters. (2) Number of decubitus ulcer pro-
cedures. (3) Older age. (4) Patients with co-morbidities
such as diabetes mellitus, hypertension.
Proteinuria is likely in spinal cord injury patients, who
did not receive antimuscarinic drugs to reduce intravesical
pressures and therefore, are at high risk for developing
reflux nephropathy and consequently proteinuria [5].
When spinal cord injury patients develop glomerulo-
sclerosis as a result of recurrent urosepsis, hydrone-
phrosis, and renal calculi, they are likely to manifest
proteinuria. We report these patients in whom, we failed
to detect proteinuria in early stage. We wish to share our
experience so that spinal cord physicians are made aware
of the need to look for proteinuria in ‘at- risk’ patients and
similar medical errors do not happen again.
Case scenarios
Case 1
An 18-year-old, British male, while attending a party,
was held by the neck and thrown out in 1981. He fell on
his face and found that he could not move his limbs.
This patient had sustained C-5 tetraplegia. X-ray of
cervical spine revealed C-6/C-7 dislocation. During
rehabilitation, this patient had indwelling urethral catheter
drainage. He developed several episodes of urine infection
and received multiple courses of Ampicillin, Gentamicin,
and Amikacin. Cystogram revealed right vesicoureteric
reflux. In 1982, division of external urethral sphincter
was performed. He was prescribed Phenoxybenzamine
10 mg three times a day. Despite this, he had high
residual urine volume and he developed urine infec-
tions. Cystogram revealed persistence of right vesi-
coureteric reflux. In 1983, bladder neck resection was
performed. He was prescribed Distigmine and penile
sheath drainage was tried. In hindsight, Distigmine
could have predisposed high pressure voiding and reflux
nephropathy. This patient developed recurrent urine
infections and repeated attacks of orchitis. In 2001,
stones in right renal pelvis were treated by extracorpor-
eal shock wave lithotripsy. Subsequently, this patient
felt unwell and had rigors. Ultrasound examination
revealed left hydronephrosis and a calculus at the
ureteropelvic junction. Left ureteric stenting was done
followed by extracorporeal shock wave lithotripsy of left
renal calculus. Later, this patient developed stone in leftureter; ureteric stenting was done in another hospital.
Computed tomography revealed that the stone was
lying outside left ureter, anterior to left psoas muscle.
The ureteric wall was thickened and ureteric lumen was
narrow. Extracorporeal shockwave lithotripsy of left renal
calculus was performed. Subsequently, the ureteric stent
could not be removed because of encrustations over the
proximal coil. Extracorporeal shock wave lithotripsy of
encrustations over proximal coil of ureteric stent was
performed. The ureteric stent was then removed. A
month later, this patient developed temperature and
shivering. Ultrasound revealed moderate left sided
hydronephrosis with mildly reflective urine in the col-
lecting system, suspicious of infection. Left ureteric
stenting was done and the patient received Gentamicin.
During follow-up, the stent was removed, but a new
stent could not be inserted. He developed temperature
and rigors. Left nephrostomy was performed in 2009.
Nephrostomy tube was being changed every 6–8 weeks.
In 2012 this patient became unwell. Ultrasound revealed
hydronephrotic right kidney with stone in pelviureteric
junction. Right nephrostomy was performed. Extracor-
poreal shock wave lithotripsy of right renal calculus was
carried out. Computed tomography revealed residual
stone fragments and cortical scarring (Figure 1) Results
of laboratory investigations are given in Table 1.
He was prescribed Ramipril 2.5 mg daily. There was
no side-effect to Ramipril. This patient continues to
have bilateral nephrostomy drainage. Blood pressure:
144/62 mm Hg. He comes to spinal unit twice a week
for change of nephrostomy dressings.
Case 2
A British white male sustained T-4 complete paraplegia
in a motor bike accident in 1988. The lower urinary tract
had been managed by penile sheath drainage, He was
advised intermittent catheterisations and use oxybutynin
bladder instillations; but this was not continued. Video-
urodynamics was not performed Blood urea: 3.0 mmol/L.
Creatinine: 47 umol/L. In 1995, this patient developed
vomiting and temperature. Blood urea: 22.3 mmol/L;
creatinine: 299 umol/L. Ultrasound of kidneys revealed
marked hydronephrosis of right kidney and minor
hydronephrosis of left kidney. nephrostomy drainage of
both kidneys was performed in March 1995. In April
1995, cystoscopy and bilateral ascending ureterogram
were performed. Right ascending ureterogram revealed
partial pelviureteric junction obstruction. A JJ stent was
inserted. Left ascending ureterogram revealed a stone
just below pelviureteric junction obstruction. Electrohy-
draulic lithotripsy was carried out; stone was partially
fragmented; a 7 French JJ stent was inserted. In June
1995, blood urea was 4.2 mmol/L; creatinine: 70 umol/L.
Right ureteric stent was removed. Extracorporeal shock
Figure 1 Case 1: Computed Tomography of kidneys, coronal section. (A) Left kidney. Calculus in lower calyx; left nephrostomy in place;
renal outline is irregular due to cortical scarring. (B) Right kidney: stone in lower pole; right nephrostomy in place; cortical margin is irregular.
Calcification of aorta is seen.
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September 1995, left ureteric stent was removed. In
November 1995, both nephrostomy tubes were removed.
In 1998, intravenous urography revealed right hydrone-
phrosis. Anderson Hine’s pyeloplasty was performed for
right pelviureteric junction obstruction. In 2000, pus was
pouring out of left nephrostomy scar. Computed tomog-
raphy revealed left mid-pole renal abscess with extension
to perinephric abscess. This patient improved with anti-
biotic therapy (gentamicin and metronidazole). In 2005,
this patient developed fever with rigors he developed
multi-organ failure requiring ventilation and noradren-
aline infusion. Ultrasound scan revealed bilateral hydro-
nephrosis with multiple stones in left kidney. Bilateral
percutaneous nephrostomy were carried out. X-ray ofTable 1 Results of laboratory investigations of Case 1
▪ Urea: 4.9 mmol/L
▪ Creatinine: 52 umol/L
▪ Haemoglobin: 152 g/L
▪ HbA1c: 35 mmol/mol
▪ Serum total protein: 69 g/L
▪ Albumin: 41 g/L
▪ Urine microalbumin: 239.1 mg/L
▪ 24-hours urine protein: 0.32 g/24 hours (0.10 g/L) from left kidney
and 0.46 g/24 hours (0.19 g/L) from right kidney.
▪ Urine electrophoresis: No monoclonal bands were detected.
▪ Serum Glomerular Basement Membrane antibody screen: Negative
▪ Serum Neutrophil Cytoplasmic Antibody screen by florescence: Positive
p-ANCA not MPO. The significance of this antibody is unknown.
▪ Serum Anti-Proteinase (c-ANCA): Negative
▪ Serum Anti-Myeloperoxidase (p-ANCA): Negativechest revealed generalized infiltration of both lung fields.
Tracheostomy was performed. With Tazocin therapy, he
improved. Extracorporeal shock wave lithotripsy of left
renal calculi was carried out. In 2006, balloon dilatation of
right pelviureteric junction was performed. Left ureteric
catheterization was not possible; Terumo guide wire could
be passed through left ureteric orifice for one cm only.
A stent was introduced antegrade in left ureter and
nephrostomy was removed. In 2007, Right nephrostomy
and left ureteric stent were replaced at regular intervals. In
2011, ultrasound examination revealed the right kidney
measuring 9.4 cm with diffuse cortical scarring; cortical
thinning was noted. Left kidney was grossly hydronephro-
tic with diffuse cortical thinning. MAG-3 renogram, per-
formed in 2011, revealed relative function of 24% by left
kidney compared with 76% for the right kidney. Uptake
and drainage of left kidney had deteriorated from the
earlier study with a persistent obstructive pattern.
Drainage of right kidney was impaired. The findings
were consistent with deterioration in cortical function
of the left kidney. In 2012, this patient developed sepsis
following blockage of right nephrostomy. Right nephrost-
omy was changed; about 200 ml of thick purulent fluid
was drained. Left nephrostomy was performed two weeks
later. Subsequently, left ureteric stent was removed. In
2013, computed tomography revealed tiny calculi in
mid and lower pole of right kidney; 10 mm calculus at
the lower pole of left kidney; cysts in left kidney; cortical
scarring in both kidneys (Figure 2).
Urea: 6.9 mmol/L. Creatinine: 99 umol/L. Haemo-
globin: 144 g/L. eGFR: 67 ml/min/1.73 m. Cholesterol:
7.8 mmol/L; Triglycerides: 2.4 mmol/L; LDL Cholesterol:
5.5 mmol/L; Cholesterol/HDL Ratio: 7. In February
2013, Right nephrostomy: Urine protein: 2.31 g/L; 24 hours
Figure 2 Case 2: Computed Tomography of kidneys, coronal view. (A) Right kidney: tiny calculus in lower pole; nephrostomy is in place.
Outline of kidney is irregular due to cortical scarring. (B) Left kidney calculus in lower pole; nephrostomy is seen in place. Renal outline is irregular.
Table 2 Results of blood tests of Case 2
▪ Serum Total Protein: 77 g/L; Albumin: 41 g/L.
▪ Serum protein electrophoresis: No abnormal bands detected.
▪ Serum immunoglobulins:
▪ Serum Immunoglobulin G: 18.09 g/L (reference range: 6.0-16.0)
▪ Serum Immunoglobulin A: 4.14 g/L (reference range: 0.8 – 2.8)
▪ Serum Immunoglobulin M: 2.08 g/L (reference range: 0.5 – 1.9).
Polyclonal increase of immunoglobulins was associated with infection,
liver disease, or various connective tissue diseases.
▪ Serum Connective Tissue Diseases screen: Negative (tested for U1RNP,
SS-ARo (60 kDa, 52 kDa), SS-B/La, Centromere B, Scl-70, Jo-1, Fibrillarin,
RNA Pol III, Rib-P, PM-Scl, and PCNA, Mi-2 proteins and Sm proteins
and dsDNA).
▪ Serum Glomerular Basement Membrane Screen: Negative. GBM
Quantification: less than 0.8 Elisa units (0–6.9).
▪ Serum Neutrophil Cytoplasmic Antibody Screen by fluorescence:
Negative.
▪ Serum Anti-Proteinase 3 (c-ANCA): Negative 0.2 IU/ml (0–1.9).
▪ Serum Anti-Myeloperoxidase (p-ANCA): Negative (less than 0.2 (0–3.4).
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protein: 0.73 g/L; 24 hours urine protein: 0.42 g/24 hours.
In October 2013, urine from left nephrostomy: Urine pro-
tein: 2.10 g/L. Protein:creatinine ratio: 488.4 mg/mmol.
Right nephrostomy: 0.61 g/L Urine Protein: creatinine
ratio: 112.96 mg/mmol. Results of additional tests are
given in Table 2.
In view of the risk of progression of chronic kidney
disease and the need to lower the proteinuria to protect
his cardiovascular risk, this patient was prescribed
Ramipril 1.25 mg a day and kidney function was
checked a week later. Plan was to monitor the patient
and if he developed any symptom due to low blood
pressure, then the medication would have to be stopped.
He was also prescribed Atorvastatin 10 mg daily. Three
weeks later, cholesterol level decreased to 4.5 mmol/L;
LDL cholesterol level decreased to 3.0 mmol/l. This
patient did not develop side-effects to Ramipril; the
dose of Ramipril was increased to 2.5 mg daily. Blood
pressure was 119/70 mm Hg. This patient continues to
have bilateral nephrostomy drainage. He is currently
employed as Information Technologist in the local
government council. He visits spinal unit once a week
for change of nephrostomy dressings.
Case 3
A 37-year-old British male, in the year 1987, dived into
the sea, and was found floating on the water face down.
He was brought out of the water and taken to Emergency.
Clinical examination revealed complete tetraplegia at C-6
level. Division of external urethral sphincter at 12 o’ clock
position from just below bladder neck to bulb, dividing
the sphincter completely, was performed in 1991. This
patient managed his bladder by penile sheath along with
oral Prazosin 500 micrograms twice a day. In 1996, thispatient started having intermittent catheterisations twice a
day. This patient was not prescribed antimuscarinic drugs
and status of neuropathic bladder was not assessed by
video- urodynamics. In 2000, during routine follow-up,
calculus in upper pole of left kidney was detected. In
2001, ultrasound revealed calculi in mid- and lower
poles of left kidney. In 2003, MAG-3 renogram showed
relative function of left kidney to be 16% and 84%
in right kidney. In 2004, left ureteric stenting was done
and stone in urinary bladder was treated by electrohy-
draulic lithotripsy. Extracorporeal shock wave lithotripsy
of left renal calculus was carried out and follow-up X-ray
of kidney revealed complete clearance. In 2008, this
patient developed severe urine infection. Computed
tomography of kidneys revealed a 7.6 cm × 7 cm
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lower pole of right kidney. There was a 2 cm staghorn
calculus in the renal pelvis. Left kidney appeared atro-
phic with multiple cortical scarring and at least two
calculi in renal pelvis. Under CT guidance, abscess
located in right perinephric region was drained. An 8
French pigtail catheter was inserted to drain the pus.
Microbiology of pus revealed growth of Enterococcus
faecalis, Streptococcus milleri and mixed anaerobes.
After antibiotic therapy, a stent was inserted in right
ureter. Extracorporeal shockwave lithotripsy was per-
formed, which resulted in complete fragmentation of
stones in right kidney. Then right ureteric stent was
removed. In 2009, this patient developed stones in left
kidney, and renal calculi were treated by extracorporeal
shock wave lithotripsy. In 2011, this patient developed
bilateral renal calculi. Extracorporeal shock wave litho-
tripsy of right renal calculi was carried out. In 2012, this
patient became unwell. Ultrasound revealed marked
hydronephrosis of left kidney. Left nephrostomy was
performed. Extracorporeal shock wave lithotripsy of left
renal calculi was carried out. He developed left ischial
pressure sore and the sore was repaired under general
anaesthesia in 2012. In 2013, multiple calculi were
detected in right kidney. Subsequently, this patient
developed urosepsis. Ultrasound revealed acute onset
right hydronephrosis with stone in renal pelvis. Urgent
right nephrostomy was performed. After he recovered
from this episode of acute infection, extracorporeal
shock wave lithotripsy of right renal calculi was carried
out. Computed tomography revealed cortical scarring of
both kidneys. (Figure 3) Subsequently, ureteroscopy and
laser lithotripsy of residual stones were carried out on
both sides in two separate sessions. Results of urine and
blood tests are given in Table 3.Figure 3 Case 3: Computed Tomography of kidneys, coronal view. (A
calcification in aorta. (B) stent in right ureter; nephrostomy in left kidney; stHe was prescribed Ramipril 2.5 mg daily. At present,
this patient does not have nephrostomy or ureteric
stents. Blood pressure: 88/65 mm Hg. Urea: 6.5 mmol/L.
Creatinine: 121 umol/L. Urine Protein: 0.33 g/L. Urine
Protein: Creatinine ratio: 57 mg/mmol. He manages his
bladder by penile sheath drainage and intermittent cathe-
terisations. He lives in his home with his family and has
been doing well.
Discussion
Proteinuria in spinal cord injury patients
The lesson from these cases is that health professionals
should look for proteinuria in spinal cord injury pa-
tients with following risk factors: (1) those, who have
not been taking anticholinergic drugs and at risk for
developing vesicoureteric reflux and reflux nephropa-
thy. (2) Patients, in whom vesicoureteric reflux has been
demonstrated in video-urodynamics. (3) Patients with
recurrent urine infection, hydronephrosis, renal scar-
ring detected during imaging studies. (4) Patients with
chronic infection – e.g. pressure sores, chronic osteo-
myelitis. (5) Longstanding spinal cord injury, although
it is difficult to define a cutoff point, whether we should
screen for proteinuria after ten years or twenty years.
(6) Older patients. (7) Patients with co-morbidities like
diabetes mellitus, hypertension.
In spinal cord injury patients, serum creatinine level
may be low because of reduced muscle mass; estimated
glomerular filtration rate may be misleadingly high.
Serum creatinine level is not sensitive in detecting
early deterioration of renal function in patients with
spinal cord injury [6]. Kaji and associates [7] found serum
creatinine to be within normal limits or only minimally
elevated in spinal cord injury patients, despite significant
reduction in creatinine clearance. Therefore, caution) right kidney: nephrostomy in place; several calculi in renal pelvis, and
one in left renal pelvis; and left kidney is atrophic.
Table 3 Results of laboratory investigations of Case 3
▪ Urea: 5.3 mmol/L.
▪ Creatinine: 121 umol/L.
▪ Haemoglobin: 117 g/L.
▪ July 2013: Urine protein: 1.43 g/L
▪ Protein:creatinine ratio: 201.4 mg/mmol.
▪ October 2013: Urine protein: 1.51 g/L.
▪ December 2013: Urine protein: 1.57 g/L.
▪ Urine protein from left nephrostomy: 0.52 g/24 hours;
▪ Urine protein from right nephrostomy: 0.53 g/24 hours.
▪ Serum total protein: 61 g/L; Albumin: 32 g/l.
▪ Serum IgG: 13.29 g/L (reference range: 6.00-16.00).
▪ Serum IgA: 2.85 g/L (reference range: 0.80-4.00).
▪ Serum IgM: 0.72 g/L (reference range: 0.50-2.00).
▪ Serum protein electrophoresis: No abnormal bands were detected.
▪ Serum Glomerular Basement Membrane Screen: Negative.
▪ Serum Neutrophil Cytoplasmic Antibodies Screen by fluorescence:
Negative.
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creatinine and eGFR in spinal cord injury patients.
The optimal method for proteinuria detection in chronic
spinal cord injury
Alshayeb and associates [8] carried out a retrospective
analysis in 219 veterans with spinal cord injury, com-
paring Dipstick protein analysis and 24-h urine protein
excretion. These researchers concluded that urine
collections of 24-hour are still needed in the chronic
spinal cord injury population for accurate detection
of clinically significant proteinuria. Dipstick protein
analysis may not reliably detect low-grade clinical pro-
teinuria, whereas a urine protein: creatinine ratio below
0.3 may be used to rule out clinical range proteinuria.
Significance of proteinuria in spinal cord injury patients
Spinal cord injury patients with proteinuria had more
impaired renal function and increased mortality com-
pared with spinal cord injury patients without protein-
uria. Vaziri and associates [9] observed that 48% of 43
male hemodialysis patients with end-stage renal dis-
ease complicating spinal cord injury, exhibited neph-
rotic range proteinuria. Greenwell and associates [10]
studied the predictive value of proteinuria and creatin-
ine clearance in relation to mortality in patients with
spinal cord injury. The presence of either proteinuria
with protein of 500 mg/d or greater, or creatinine
clearance less than 60 mL/min is associated independ-
ently with increased mortality in the chronic spinal
cord injury population. The presence of both condi-
tions further increases this risk.Proteinuria and progressive renal damage
Independent of the underlying causes, chronic protein-
uric glomerulopathies have in common a sustained or
permanent loss of selectivity of the glomerular barrier to
protein filtration. Glomerular sclerosis is the progressive
lesion beginning at the glomerular capillary wall, the site
of abnormal filtration of plasma proteins. Injury is trans-
mitted to the interstitium favoring the self-destruction of
nephrons and eventually of the kidney. The results of
experimental and clinical studies show that proteinuria
may accelerate kidney disease progression to end-stage
renal failure. Evidence indicates that this process occurs
through multiple pathways, including induction of tubu-
lar chemokine expression and complement activation
that lead to inflammatory cell infiltration in the intersti-
tium and sustained fibrogenesis. Macrophages are prom-
inent in the interstitial inflammatory infiltrate. This cell
type mediates progression of renal injury to the extent
that macrophage numbers in renal biopsy predict renal
survival in patients with chronic renal [11].
How to slow the progression of kidney disease in spinal
cord injury patients with proteinuria?
Proteinuria is associated with a faster progression of
kidney disease. In general, reduction in proteinuria
correlates with slowing the progression of kidney disease.
In controlled trials in Chronic Kidney Disease, Angiotensin
Converting Enzyme (ACE) inhibitors and Angiotensin
Receptor Blockers (ARB) reduce protein excretion by
approximately 35% to 40%. In experimental animals,
enhanced glomerular capillary pressure causes impaired
glomerular permeability to proteins and permits exces-
sive proteinuria. Reabsorption of filtered proteins can
injure the tubular cells and interstitium of the kidney by
activating intracellular events and the release of vaso-
active and inflammatory mediators. Both ACE inhibitors
and ARBs reduce the intraglomerular pressure and
thereby, reduce the glomerular permeability barrier to
proteins and limit proteinuria and filtered protein-
dependent inflammatory signals [12].
Guideline for prescribing angiotensin converting enzyme
inhibitors or angiotensin receptor blockers in patients
with proteinuria
National Institute for Health and Clinical Excellence [8]
in England recommends ACE inhibitors/ARBs in pa-
tients with diabetes mellitus irrespective of whether
they have hypertension or not, if albumin:creatinine ra-
tio is > 2.5 mg/mmol (men) or > 3.5 mg/mmol (women).
If a patient does not have diabetes mellitus, but has
hypertension and albumin: creatinine ratio < 30 mg/mmol,
antihypertensive treatment should be instituted. In
patients with hypertension and albumin: creatinine
ratio ≥ 30 mg/mmol, Angiotensin Converting Enzyme
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prescribed [13].
In patients with albumin: creatinine ratio ≥ 70 mg/mmol
with or without hypertension or cardiovascular disease,
Angiotensin Converting Enzyme inhibitors or Angiotensin
Receptor Blockers should be prescribed [13].
Therapeutic targets for ACE inhibitors and ARBs in
chronic kidney disease are as follows [14]: (1) Blood
pressure should be <130/80 mm Hg or lower in patients
with spot urine total protein to creatinine ratio > 500–
1,000 mg/g (56.8 – 113.0 mg/mmol). (2) Spot total
protein to creatinine ratio should become less than
500–1,000 mg/g (56.8 – 113.0 mg/mmol).
Lessons learnt from failure
Spinal injury patients with bladder involvement are well
known to be at risk of high bladder residual volumes, urin-
ary infections and stone formation. Over time these com-
bined insults do take their toll on kidney function. While
renal excretory function is often monitored by blood tests
that measure urea and creatinine levels, proteinuria is not
actively looked for. Proteinuria can occur when the blood
tests are relatively normal, and should be acted upon as a
sign of renal disease. Chronic kidney disease thus identified
via blood or urine tests requires the same intensity of inter-
vention as any other cause such as diabetes. In addition to
the usual measures of correction of electrolyte and acid
base imbalances, tight blood pressure control and cardio-
vascular risk reduction, spinal patients require added focus
on prevention and early treatment of infections, and de-
compression of high pressure urinary systems. In those
with more severe kidney damage, decisions should be
made in advance with the patient on treatment ceilings
and in those who are appropriate for dialysis, prepar-
ation for the same made in a planned manner so that
their transition to renal replacement is smooth. Our paper
highlights the need to detect proteinuria as marker for
renal damage and the treatment of proteinuria as a
means to defend renal function or at the very least, re-
tard progression of renal disease.
We had been focusing on the urological care of these
three patients; prescribing antibiotics for urine infection;
providing drainage to obstructed kidneys; breaking urinary
calculi by extracorporeal shockwave lithotripsy, percutan-
eous nephrolithotripsy, and ureteroscopic lithotripsy We
did not routinely investigate these patients for proteinuria
and co-existing renal disease until recently. We missed the
opportunity for early detection of proteinuria and we
failed to prescribe ACE inhibitors to slow the progression
of kidney damage at an earlier stage.
Take home message
(1) Spinal cord injury patients, who have not undergone
video-urodynamics and not been taking antimuscarinicdrugs are at risk for developing reflux nephropathy and
proteinuria. (2) Patients who develop pressure sores,
recurrent urosepsis, renal calculi, and hydronephrosis
may develop proteinuria due to glomerulosclerosis.
These patients should be tested for proteinuria during
follow-up. (3) In the absence of other renal diseases
causing proteinuria, spinal cord injury patients with
significant proteinuria may be prescribed angiotensin-
converting enzyme inhibitor or angiotensin-II receptor
antagonist to slow progression of chronic renal disease
and reduce the risk of cardiovascular mortality. (4)
These spinal cord injury patients require careful moni-
toring of blood pressure and renal function while taking
angiotensin-converting enzyme inhibitor or angiotensin-II
receptor antagonist, as tetraplegic patients are likely to
have low blood pressure, and some patients may have
reduced glomerular filtration rate as well.
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